Skip to main content

VPRIV FDA Approval History

FDA Approved: Yes (First approved February 26, 2010)
Brand name: VPRIV
Generic name: velaglucerase alfa
Dosage form: for Injection
Company: Shire plc
Treatment for: Gaucher Disease

VPRIV (velaglucerase alfa) is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with Type 1 Gaucher disease.

Development timeline for VPRIV

DateArticle
Feb 26, 2010Approval FDA Approves VPRIV to Treat Gaucher Disease
Nov  4, 2009FDA Grants Priority Review for Shire's velaglucerase alfa for Type 1 Gaucher Disease
Sep  2, 2009Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
Jul  7, 2009Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease

See also

VPRIV (velaglucerase alfa) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer